Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report)’s stock price traded down 3.3% on Thursday . The company traded as low as C$3.18 and last traded at C$3.19. 14,359 shares were traded during trading, an increase of 94% from the average session volume of 7,410 shares. The stock had previously closed at C$3.30.
Eupraxia Pharmaceuticals Price Performance
The business has a fifty day moving average of C$3.02 and a 200-day moving average of C$2.76.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis.
See Also
- Five stocks we like better than Eupraxia Pharmaceuticals
- The 3 Best Blue-Chip Stocks to Buy Now
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- Do ETFs Pay Dividends? What You Need to Know
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- Which Wall Street Analysts are the Most Accurate?
- MarketBeat Week in Review – 12/16 – 12/20
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
